Skip to main content
NCBI home page
Frontiers in Pharmacology logoLink to Frontiers in Pharmacology
. 2014 May 9;5:103. doi: 10.3389/fphar.2014.00103

Pharmacogenomics of human P450 oxidoreductase

Amit V Pandey 1,2,*, Patrick Sproll 2
PMCID: PMC4023047  PMID: 24847272

Abstract

Cytochrome P450 oxidoreductase (POR) supports reactions of microsomal cytochrome P450 which metabolize drugs and steroid hormones. Mutations in POR cause disorders of sexual development. P450 oxidoreductase deficiency (PORD) was initially identified in patients with Antley–Bixler syndrome (ABS) but now it has been established as a separate disorder of sexual development (DSD). Here we are summarizing the work on variations in POR related to metabolism of drugs and xenobiotics. We have compiled mutation data on reported cases of PORD from clinical studies. Mutations found in patients with defective steroid profiles impact metabolism of steroid hormones as well as drugs. Some trends are emerging that establish certain founder mutations in distinct populations, with Japanese (R457H), Caucasian (A287P), and Turkish (399–401) populations showing repeated findings of similar mutations. Most other mutations are found as single occurrences. A large number of different variants in POR gene with more than 130 amino acid changes are now listed in databases. Among the polymorphisms, the A503V is found in about 30% of all alleles but there are some differences across different population groups.

Keywords: P450 oxidoreductase, P450 oxidoreductase deficiency, Antley–Bixler syndrome, steroid metabolism, disorders of sexual development, drug metabolism, P450c17, aromatase

Introduction

Cytochrome P450 reductase (POR) has a major role in metabolism of drugs and steroids (Flück et al., 2007; Pandey and Flück, 2013; Riddick et al., 2013) (Figure 1). All microsomal cytochrome P450 get electrons from nicotinamide adenine dinucleotide phosphate (NADPH) through POR (Zanger and Schwab, 2013) (Figure 2). A single gene of 71,754 bp located on chromosome 7 (locus 7q11.23) encodes human POR (Table 1). The human POR gene has one non-coding exon and 15 protein-coding exons and encodes a 680 amino acid membrane bound protein (RefSeq protein: NP_000932, UniProt P16435). Disruption of POR affects all microsomal P450 enzyme activities (Flück et al., 2007; Pandey and Flück, 2013). POR also supplies electrons to many other interaction partners. POR knockout mice are embryonic lethal (Shen et al., 2002; Otto et al., 2003). The liver-specific knockout of POR produces mice with lower metabolism and lipid accumulation (Gu et al., 2003; Henderson et al., 2003; Porter et al., 2011).

Figure 1.

Figure 1

Open in a new tab

Role of P450 oxidoreductase in biochemical pathways. POR is required for multiple metabolic processes especially the microsomal P450 enzymes involved in metabolism of xenobiotics.

Figure 2.

Figure 2

Open in a new tab

Electron transfer from NADPH to redox partners of POR. NADPH binds to POR located into the endoplasmic reticulum, and donates electrons which are received by FAD. Electron transfer to FAD causes a conformational change that brings together the FAD and FMN domains and electrons are transferred from FAD to FMN. The FMN domain of POR interacts with the P450s and other redox partners and completes the final step of electron transfer.

Table 1.

Database accession numbers for human POR.

RefSeq Protein NP_000932
RefSeq RNA NM_000941
UniGene Hs.354056
Uniprot P16435
GeneID 5447
GeneCards GC07P075528
Ensembl ENSG00000127948
HGNC HGNC:9208
Open in a new tab

Cytochrome P450 oxidoreductase deficiency (PORD); (OMIM: 613571 and OMIM: 201750) is a form of congenital adrenal hyperplasia (Flück et al., 2004; Miller et al., 2004; Pandey et al., 2004; Flück and Pandey, 2013). Clinical symptoms of PORD were described in a 46,XY patient with disorder of sexual development (DSD) (Peterson et al., 1985). Sequencing of the POR gene in a Japanese 46,XX girl with a metabolic profile of steroid deficiency and symptoms of Antley–Bixler Syndrome (ABS) led to the characterization of PORD (Flück et al., 2004). Skeletal malformation in many ABS patients with ambiguous genitalia and defective steroid metabolism have now been linked to PORD (Huang et al., 2005). PORD is now listed as a separate metabolic disorder (Huang et al., 2005). An overview of reported cases shows that PORD disrupts steroid biosynthesis in adrenal gland and gonads (Huang et al., 2005; Dhir et al., 2007; Pandey et al., 2007; Flück et al., 2011a). This often leads to genital ambiguity at birth in both male and female. The absence of testosterone (T)/dihydrotestosterone (DHT) leads to development of female external genitalia (Flück and Pandey, in press). The presence of T/DHT triggers the formation of male genitalia. In humans the testosterone is mainly produced in testes by a process that starts by the conversion of pregnenolone to 17-hydroxypregnenolone (17-OHPreg) and dehydroepiandrosterone (DHEA) by the enzyme CYP17A1 in the adrenal (Miller and Auchus, 2011) (Figure 3). Like other microsomal P450 CYP17A1 requires POR (Miller and Auchus, 2011; Pandey and Flück, 2013). Aromatase converts androgens to estrogens and also requires POR (Pandey et al., 2007; Flück et al., 2011a; Bouchoucha et al., 2014). Thus, a defective POR affects sexual development (Flück and Pandey, 2011; Fukami et al., 2013) in both male and female. Many cases still do not have final diagnosis and other genes may be involved (Flück and Pandey, in press). Recently we have reported the first human mutations in aldo-keto reductases AKR1C2 (OMIM: 614279) and AKR1C4 (OMIM: 600451) (Flück et al., 2011b). This established two distinct pathways for the biosynthesis of androgens in fetal testis for control of sexual differentiation between male and female (Flück et al., 2011b; Biason-Lauber et al., 2013a,b; Flück and Pandey, in press). POR also plays a role in this alternate pathway (Biason-Lauber et al., 2013a; Pandey and Flück, 2013) (Figure 3). A large number of POR variants containing more than 130 amino acid changes in the POR protein have now been reported (Figure 4) by multiple researchers, and a list of variants in human POR is available at CYP allele website (www.cypalleles.ki.se/por.htm) (Huang et al., 2008; Sim et al., 2009; Flück et al., 2011a; Tomkova et al., 2012).

Figure 3.

Figure 3

Open in a new tab

Role of POR in biosynthesis of androgens in classic and alternate pathways. The classic pathway proceeds from transfer cholesterol to mitochondrion through steroidogenic acute regulatory protein (StAR). In the mitochondrion cholesterol is converted to pregnenolone by CYP11A1. The biosynthesis process then continues from pregnenolone to 17OHPreg and DHEA to androstenedione or androstenediol and then to testosterone in testicular Leydig cells. Testosterone (T) is converted to dihydrotesterone (DHT) in genital skin. The backdoor pathway proceeds from 17OHPreg to 17OHProg, 17OH-DHP, 17OH-Allo, androsterone, androstanediol (A'diol) and then to DHT in the testis. Abbreviations: CYP11A1, P450scc, cholesterol side-chain cleavage enzyme; StAR, steroidogenic acute regulatory protein; FDX1, Adrenodoxin; FDXR, NADPH adrenodoxin oxidoreductase; CYP17A1, P450c17, 17α-hydroxylase/17,20-lyase; HSD3B2, 3β HSD2, 3β-hydroxysteroid dehydrogenase, type 2; CYB5, cytochrome b5; POR, P450 oxidoreductase; HSD17B3, 17β HSD3, 17β-hydroxysteroid dehydrogenase, type 3; and SRD5A2, 5α-reductase, type 2. The alternative pathway has four additional enzymes: SRD5A1, 5α-reductase, type 1; AKR1C2, Aldo-keto reductase 1C2, 3αHSD3; and AKR1C4, Aldo-keto reductase 1C4, 3αHSD1, for reductive 3αHSD activity; and HSD17B6, 17β HSD6, 17β-hydroxysteroid dehydrogenase, type 6; and/or AKR1C2/4 for oxidative 3αHSD activity. Full steroid names: 17OHPreg, 17-hydroxypregnenolone; 17OHProg, 17-hydroxyprogesterone; 17OH-DHP, 17-hydroxydihydroprogesterone (5α-pregnan-3α,17α-ol-20-one); 17OH-Allo, 17-hydroxyallopregnanolone (5α-pregnan-3α,17α-diol-20-one; P'diol); A'diol, androstanediol; T, testosterone; DHT, dihydrotestosterone, DHEA, dehydroepiandrosterone.

Figure 4.

Figure 4

Open in a new tab

POR protein sequence showing missense mutations identified in patients and variations from normal human population. Mutation found in patients are indicated with red triangle while variants identified from healthy individuals are indicated with blue triangle. Amino acids are colored based on chemical properties; acidic residues (D, E) are in red, basic residues (H, R, K) are in blue, and rest of the polar amino acids (N, C, Q, S, T, and Y) are in green. Data were compiled from information available in NCBI SNP database and POR listing at CYPallele database (Sim et al., 2009) as of April 2014.

This review describes current status of information and research on disease related as well as naturally occurring variants of the POR gene. We have collected data on reports of PORD to summarize the current information on effects of POR mutations on enzymatic activities of redox partners. In addition, we have compiled the list of naturally occurring variants in POR gene that have been reported by researchers specifically sequencing the POR gene in distinct populations. We have also included information on POR variants available in genomic databases from large scale sequencing studies. Recently many POR variants have been studied for effects on drug metabolizing enzymes. We have also summarized studies describing the impact of individual POR variants on in vitro as well as in vivo drug metabolism cytochrome P450 activities. We have labeled the POR variants found in patients with disorders of steroid metabolism as “mutants” and variants identified from normal human population as “polymorphisms” (Figure 4). List of POR variants was compiled from publication of PORD case reports, POR sequencing studies, and human genome sequencing projects available through NCBI databases (http://www.ncbi.nlm.nih.gov).

POR and steroid metabolism

PORD was identified as a DSD resulting from disruption of steroid metabolizing cytochrome P450 activities (Flück et al., 2004; Pandey et al., 2004). After the identification of POR variants in normal human population, early reports analyzed the impact of POR variants on three microsomal cytochrome P450 involved in steroid metabolism (CYP17A1, CYP19A1, and CYP21A2) (Flück et al., 2004; Huang et al., 2005; Dhir et al., 2007; Pandey et al., 2007). A large number of POR mutations or polymorphisms (Huang et al., 2005; Flück et al., 2011a) have been studied and analyzed based on known structures of POR (Xia et al., 2011; Pandey and Flück, 2013). Many mutations in POR found in patients are in co-factor binding sites and cause severe POR deficiency. The p.A115V variation first found in patients seems to be a polymorphism (Huang et al., 2008) and shows similar to wild type activity in CYP17A1 assays. The p.T142A mutation is close to FMN binding site but shows more than 50% of WT activity (Huang et al., 2005). The mutation p.Q153R also near the FMN binding site, had reduced POR activity in CYP17A1 assays (Table 2 and Figure 5) (Huang et al., 2005). An XY patient of Canadian origin with symptoms of 17-, 21-hydroxylase had POR mutation p.G188_V191dup but enzyme activity data are not available (Krone et al., 2012). The mutation p.A287P is most common in patients from Europe (Huang et al., 2005). It retains 20–40% of WT activity in CYP17A1 assays (Table 2) but had no effect on either CYP19A1 (Flück et al., 2004; Huang et al., 2005; Pandey et al., 2007) or CYP21A2 activity (Dhir et al., 2007). The polymorphism p.R316W shows normal activity in most assays (Huang et al., 2005; Pandey and Flück, 2013). The mutation p.P399_E401del found in two unrelated Turkish families (Flück et al., 2011a) had 68–85% of WT activity in different P450 assays (Flück et al., 2011a). Polymorphism p.G413S was identified in a sequencing study by Bioventures Inc. (Solus et al., 2004), retains wild type activity in many assays (Table 3) (Huang et al., 2005). A DSD patient of Pakistani origin (17 and 21-hydroxylase deficiencies) had p.R498P mutation (Krone et al., 2012). No enzymatic data for p.R498P are available. The variations p.A503V and the p.G504R have >50% activity (Huang et al., 2005). A link between p.A503V variant of POR and altered steroid profile in normal population was not found (Utriainen et al., 2012). The mutation p.G539R had <10% activity in the 17,20 lyase assay and 46% activity in the 17α-hydroxylase assay (Huang et al., 2005). The mutation p.C569Y in human POR (Flück et al., 2004) had 13% of 17,20 lyase activity and 28% of 17α-hydroxylase activity (Huang et al., 2005). The polymorphism p.R600W has 7–60% of WT activity in different assays (Huang et al., 2008). The p.C569Y mutation was compound heterozygote together with p.V608F (Flück et al., 2004). The p.V608F retained 57% of 17,20 lyase activity and 80% of 17α-hydroxylase activity (Table 2 and Figure 5) (Huang et al., 2005; Pandey et al., 2007). Both p.C569Y and p.V608F had more severe effects on CYP19A1 activity than on CYP17A1 activities (Flück et al., 2004; Huang et al., 2005; Pandey et al., 2007). The p.H628P affected both CYP17A1 and CYP21A2 activities to similar extent (Dhir et al., 2007). The p.Y607C had greater effects on CYP17A1 and CYP19A1 activities but CYP21A2 activity was 80% of WT (Idkowiak et al., 2010). There were no severe malformations in the p.Y607C patient (Huang et al., 2005; Idkowiak et al., 2010). A normal steroid profile also suggests normal activities of steroidogenic enzymes in vivo (Idkowiak et al., 2010). The p.V631I retained 40–50% of activity in the CYP17A1 assays. Deletion of F646 had no effect on 17α-hydroxylase activity but caused a 54% reduction in 17,20 lyase activity (Huang et al., 2005). Other reported mutants in the region p.Y578C and p.E580Q were not tested in enzymatic assays (Pandey and Flück, 2013).

Table 2.

Influence of POR variants found in patients with disorder of sexual development, on the enzyme activities of its redox partners.

POR DBSNP id CYP3A4 HO-1 Cyt c red NADPH Oxi CYP17A1 17OH-ase CYP17A1 17,20 lyase CYP19A1 CYP1A2 CYP2C19 CYP2D6
WT – 100 100 100 100 100 100 100 100 100 100
p.T142A – 85 81 49 52 60 54 – 3 –
p.Q153R – 119 72 9 11 31 27 – 144 284 128
p.Y181D rs72552771 – – – – – – – –
p.N185K 6 1 – –
p.M263V – 76 57 9 13 92 136
p.A287P rs121912974 26 49 93 104 40 21 104 – – –
p.P339_E401del – 20 26 31 30
p.R457H rs28931608 – – 1 – 3 – 1 – – –
p.Y459H – – – – – 11 – – – –
p.V492E rs28931606 – – – – 3 – <1 – –
p.G539R rs121912976 9 – 46 8 10 33
p.L565P – 14 1 32 19 – –
p.C569Y rs28931607 32 33 18 7 28 13 51 6 –
p.L577R 5 4 46 27
p.Y607C rs72557954 – 20 76 40 7 24
p.V608F rs72552772 16 32 8 3 80 57 24 5 –
p.R616X – – – – 6 – – – – –
p.V631I rs145782750 89 96 74 23 51 40 – 6 23
p.delF646 – 88 95 36 94 97 46 – – –
Open in a new tab

Activities are shown as percentage of the wild-type POR. POR, P450 oxidoreductase. Data were compiled from previous studies (Flück et al., 2004, 2010, 2011a; Pandey et al., 2004, 2007, 2010; Huang et al., 2005, 2008; Agrawal et al., 2008, 2010; Nicolo et al., 2010; Sandee et al., 2010). The V631I and Y607C were initially found in patients but later studies established those as normal population variants. Mutations listed in bold abolish all activity. These were found in patients with severe forms of disease and affected residues are located near co-factor binding sites of POR.

Enzymes/reactions and substrates (in parenthesis) listed in this table: CYP3A4: [BOMCC (7-Benzyloxy-4-trifluoromethylcoumarin)]; HO-1: Heme oxygenase-1 (heme); Cyt c red: Cytochrome c reduction (cytochrome c); NADPH ox: NADPH oxidation (NADPH); CYP17A1 17OH-ase: (Progesterone); CYP17A1 17,20 Lyase: (17-hydroxy Pregnenolone), CYP19A1: (androstenedione); CYP1A2, CYP2C19, and CYP2D6: [EOMCC (7-ethoxy-methyloxy-3-cyanocoumarin)].

Figure 5.

Figure 5

Open in a new tab

Impact of POR variants on CYP17A1 activity. A pie chart showing the impact of POR variants on CYP17A1 17,20 lyase activity. The variants which had <5% of WT activity are grouped as red, variants with 5–25% of WT activity are in orange, variants with 25–50% of activity are in yellow, and variants with >50% activity are in green. A large number of recently identified variants from large scale sequencing studies have not been tested in enzymatic assays and these are grouped in gray color pie.

Table 3.

Influence of POR variants found in normal population on the enzyme activities of its redox partners.

POR DBSNP id CYP3A4 HO-1 Cyt c red NADPH Ox CYP17A1 17OH-ase CYP17A1 17,20 lyase CYP19A1 CYP1A2 CYP2C19 CYP2D6
WT – 100 100 100 100 100 100 100 100 100 100
p.delE53 rs72553987 57 93 73 82 156 91
p.P55L rs72553988 67 123 82 115 114 83
p.A115V rs199634961 85 95 63 41 80 71 – – –
p.D211N rs72557914 27 59 57 62 52 52
p.G213E rs72557915 111 105 57 93 174 101
p.P228L rs17853284 101 106 75 72 100 41 – 20 39
p.P284T rs72557937 16 32 14 19 – –
p.P284L rs72557938 104 153 44 82 41 27
p.E300K rs11540674 93 104 112 146 85
p.R316W BV12016# 110 96 61 77 94 141 – 109 81
p.R406H rs72557929 62 78 61 57 125 155
p.G413S BV12020# 100 104 76 100 83 110 – 73 104
p.P452L rs72557935 16 12 48 61 21 83
p.A462T rs72557936 85 69 58 66 119 100
p.V472M rs72557946 23 24 58 46 54 77
p.A485T rs72557947 36 51 68 88 80 98
p.A503V rs1057868 107 97 67 56 68 58 – 85 113 85
p.G504R BV12031# 93 107 53 47 91 103 – 82 140 –
p.R600W rs72557950 67 56 38 40 36 60
p.Y607C rs72557954 – 20 76 40 7 24
p.V631I rs145782750 89 96 74 23 51 40 – 6 23
Open in a new tab

Activities are shown as percentage of the wild-type POR. POR, P450 oxidoreductase. Data were compiled from previous reports (Flück et al., 2004, 2010, 2011a; Pandey et al., 2004, 2007, 2010; Huang et al., 2005, 2008; Agrawal et al., 2008, 2010; Nicolo et al., 2010; Sandee et al., 2010). # DBSNP id not available, these were identified in a sequencing study by Bioventures Inc. (Solus et al., 2004) and are represented as Bioventure ID numbers BVxxxxx.

Enzymes/reactions and substrates (in parenthesis) listed in this table: CYP3A4: [BOMCC (7-Benzyloxy-4-trifluoromethylcoumarin)]; HO-1: Heme oxygenase-1 (heme); Cyt c red: Cytochrome c reduction (cytochrome c); NADPH ox: NADPH oxidation (NADPH); CYP17A1 17OH-ase: (Progesterone); CYP17A1 17,20 Lyase: (17-hydroxy Pregnenolone), CYP19A1: (androstenedione); CYP1A2, CYP2C19 and CYP2D6: [EOMCC (7-ethoxy-methyloxy-3-cyanocoumarin)].

POR and drug metabolism

After the discovery of POR mutations in patients and identification several variants of POR in healthy individuals we suggested that POR variants may also impact drug metabolizing P450 enzymes since POR is necessary for activities of all microsomal P450 (Flück et al., 2004, 2007; Pandey et al., 2004; Huang et al., 2005). Variations in POR may affect many different redox partners. Many recent studies reported effects of POR variants on several drug metabolizing P450s (Agrawal et al., 2008, 2010; Hart et al., 2008; Kranendonk et al., 2008; Gomes et al., 2009; Miller et al., 2009; Oneda et al., 2009; Flück et al., 2010; Marohnic et al., 2010; Nicolo et al., 2010; Tomalik-Scharte et al., 2010) and other metabolic processes (Agrawal et al., 2010; Flück et al., 2010; Marohnic et al., 2010; Nicolo et al., 2010; Pandey et al., 2010; Sandee et al., 2010; Zhang et al., 2011). Here we are describing the reports on human studies, an overview of metabolic activities in POR mouse models by laboratories of Roland Wolf and Xin-Xin Ding has been reviewed earlier (Riddick et al., 2013).

Cytochrome P450 3A4 (CYP3A4) metabolizes a wide range of drugs and xenobiotics (Klein and Zanger, 2013; Meyer et al., 2013; Zanger and Schwab, 2013). POR mutations affect CYP3A4 activities in vitro (Nicolo et al., 2010). The POR mutant p.A287P (common mutation found in patients from “European” population) showed 75% loss of CYP3A4 activity (Table 2 and Figure 6) (Flück et al., 2010; Nicolo et al., 2010). The p.R316W and p.G413S variants had close to WT activities (Flück et al., 2010). The mutations disrupting FAD binding (p.R457H, p.Y459H and p.V492E) resulted in complete loss of CYP3A4 activity (Flück et al., 2010). POR polymorphisms p.A503V and p.G504R showed close to normal activities (Table 3) (Flück et al., 2010). POR mutations p.C569Y and p.V608F resulted in 65–85% loss of CYP3A4 and p.R616X lost all activity (Table 2) (Flück et al., 2010). The POR mutant p.Y181D resulted in almost total loss of CYP3A4 activity, while variant p.Q153R was normal and variant p.T142A had 75–80% activity (Flück et al., 2010). A larger study of POR variants with CYP3A4 suggests POR may change activities of CYP3A4 in patients (Flück et al., 2010; Nicolo et al., 2010). There may be substrate specific effects of POR variants on CYP3A4 activities. Agrawal et al. (2010) found that POR variants p.A287P and p.R457H had lower activity with all substrates. The p.Q153R had 76–94% of WT activity with midazolam and erythromycin, but showed 129–150% activity with testosterone and quinidine (Agrawal et al., 2010). The polymorphism p.A503V had 20–40% reduction in CYP3A4 activity with testosterone and midazolam. With quinidine and erythromycin the p.A503V has no significant change in activities (Agrawal et al., 2010). Studies from us and others have reported normal CYP3A4 activity with POR p.G413S (Flück et al., 2010; Moutinho et al., 2012). POR polymorphisms p.P228L, p.R316W, p.G413S, p.A503V, and p.G504R have 40–100% activity in most assays (Table 3). The p.A115V had less than 40–60% of activity, and p.V631I had 23–76% of wild-type activity (Huang et al., 2005).

Figure 6.

Figure 6

Open in a new tab

Impact of POR variants on CYP3A4 activity. A pie chart showing the impact of POR variants on CYP3A4 activity. The variants which had <5% of WT activity are grouped as red, variants with 5–25% of WT activity are in orange, variants with 25–50% of activity are in yellow, and variants with >50% activity are in green.

Agrawal et al. (2008) found POR mutations p.A287P and p.R457H resulted in almost complete loss of CYP1A2 and CYP2C19 activities (Table 2). The polymorphism p.A503V had 85% of WT activity with CYP1A2 and 113% of WT activity with CYP2C19 (Table 3). The p.Q153R, a disease-linked mutation increased activity of CYP1A2 to 144% and CYP2C19 activity to 284% of WT.

In addition to CYP3A4 the CYP2D6 is another major drug metabolizing enzyme (Zanger and Schwab, 2013). POR mutants p.A287P and p.R457H have no CYP2D6 activity with synthetic substrate EOMCC (Sandee et al., 2010). The p.A287P mutant retained 25% of WT activity with dextromethorphan and bufuralol as CYP2D6 substrates. The p.Q153R had increased activity with CYP2D6. The p.A503V resulted in activities of 85% with EOMCC, 62% with dextromethorphan, and 53% with bufuralol (Sandee et al., 2010).

There may also be differences in effects of POR variants due to presence of P450 isoforms but, this has not been explored in detail. Subramanian et al. (2012) studied the polymorphic forms of CYP2C9 (CYP2C9.1, CYP2C9.2, and CYP2C9.3) with POR variants. POR variants p.A287P and p.R457H resulted in reduced activities with all three variants of CYP2C9. The disease related variant p.R153Q had higher activities with all variants of CYP2C9 (Subramanian et al., 2012).

POR variants in different genetic populations

A study on sequencing of POR gene in 842 healthy people (Huang et al., 2008) detected 140 SNPs, and 43 of those were in ≥1% of alleles. 32 variants were in protein coding regions, 2 in untranslated exon 1U, 94 in the introns and 12 in 5′ flanking DNA. Among the 32 variations in protein coding region, 13 new variants resulted in amino acid change. The new variants were p.delE53, p.P55L, p.D211N, p.G213E, p.P284L, p.P284T, p.R406H, p.P452L, p.A462T, p.V472M, p.A485T, p.R600W, and p.Y607C. The POR polymorphism p.A503V (rs1057868) (Huang et al., 2005), was present in about 25% of all alleles (Huang et al., 2008). Most of the polymorphic variants had >40% of WT activities in different in vitro assays.

Some researchers have attempted to sequence POR gene in human liver samples to study the impact of POR variant in enzymatic studies in liver microsomes. A study of POR sequence in human liver samples by Xiao-Bo Zhong added 3 novel amino acid variations (p.K49N, p.L420M, and p.L577P) (Hart et al., 2008). The POR variant p.L577P had reduced activities in many drug metabolizing P450 assays (Hart et al., 2008). Another study of POR variation analysis by Ulli Zanger in 150 human liver samples found 43 variations with 19 SNPs in exonic regions (Gomes et al., 2009). They also found two combinatorial alleles of (p.P228L + p.A503V and p.A503V + p.V631I) and similar to previous reports, the p.A503V allele was the most common variant (Gomes et al., 2009).

Several new studies have sequenced POR gene in specific population groups. Sequencing of POR gene in 235 Japanese individuals (Saito et al., 2011) found 4 new amino acid changes (p.T29M, p.R550W, p.R570C, and p.A659T). Here p.A503V was present at a somewhat higher frequency of 0.434. A recent study sequenced POR variants in distinct Jewish populations and identified 6 novel amino acid variants, p.S102P, p.V164M, p.V191M, p.D344N, p.E398A, and p.D648N (Tomkova et al., 2012). The average minor allele frequency (MAF) of p.A503V in different reports have ranged from 0.25 to 0.45. Analysis of genomic sequence data available at NCBI SNP database shows that there are some differences among different genetic groups (Figure 7). In the Caucasian and Hispanic populations the p.A503V allele frequency is 31%, in Pacific Islanders 34%, and in Asian populations the p.A503V allele is present at 38%. In the Japanese population the p.A503V frequency is highest at 40% while the African Americans group has the lowest presence at less than 15% of all alleles. Homozygous presence of p.G5G (rs10262966, nucleotide change GGA to GGG) silent mutation has been associated with increased risk in African Americans (Haiman et al., 2007). This variant is not present in European and Asian populations and has a MAF of 0.023 in Hispanic population (Figure 8). In Sub-Saharan Africans it is present in 30% of alleles (MAF 0.297) and African Americans have the highest frequency with 40% of alleles (MAF 0.400) carrying the p.G5G variant of POR. The p.A50V variant was also tested for association with increased breast cancer risk in same study but no linkage was observed (Haiman et al., 2007).

Figure 7.

Figure 7

Open in a new tab

Allele frequencies of POR variant A503V in different population groups. The p.A503V variant of POR (rs1057868) is most common across all population groups. In various sequencing studies specifically targeting POR gene as well as large scale sequencing projects the POR p.A503V is present as most common minor allele. The average minor allele frequency in different studies ranges from 0.25 to 0.45. A closer look at the data revealed some differences. In the Caucasian and Hispanic populations the p.A503V allele is present in 31% of alleles, while in Pacific Islanders (34%) and Asian populations (38%) there is a slight but consistent increase. In the Japanese population the p.A503V frequency is highest (40%) while in African Americans it is present in less than 15% of all alleles. Alleles with p.503A are in green while p.503V is in orange. Data were compiled from information available in NCBI SNP database as of April 2014 (http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=1057868).

Figure 8.

Figure 8

Open in a new tab

Allele frequencies of POR variant G5G associated with increased breast cancer risk. The p.G5G variant of POR (rs10262966) is associated with increased risk of breast cancer when present in homozygous form in African Americans (Haiman et al., 2007). Genomic data from various sequencing projects show a clear pattern for the presence of rs10262966 in different populations. In the Caucasian and Asian populations rs10262966 is not present, while in Hispanic population it is present with a minor allele frequency of 0.023. In the Sub-Saharan African population the rs10262966 frequency is higher at 0.297 while in African Americans it is present in 40% of all alleles. Data were compiled from information available in NCBI SNP database as of April 2014 (http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=10262966).

In vivo drug clearance studies examining the impact of POR variants

Several studies have now examined the role of POR variants on in vivo drug clearance using many different standard drugs as markers. One report has described in vivo drug metabolism activities in a POR p.A287P homozygous patient and her heterozygous mother (Tomalik-Scharte et al., 2010). Genotyping of P450 enzymes predicted normal to high P450 activities in both the patient and her mother. The in vivo results showed subnormal activities of CYP1A2, CYP2C9, CYP2D6, and CYP3A4 in the patient. The heterozygous mother had reduced CYP1A2 and CYP2C9 activities. These data are in agreement with disruption of in vitro CYP3A4 activities by p.A287P variant of POR reported by us (Flück et al., 2010; Nicolo et al., 2010). In patients with PORD, the in vitro and in vivo activities of POR dependent P450 may be taken into account to modify drug dosages and supplementation with steroids.

POR variant p.A503V (POR*28) had higher levels of CYP3A activities based on midazolam clearance (Oneda et al., 2009). Yang et al have studied the effect of POR variant p.A503V on in vivo CYP3A activity in healthy Chinese men (Yang et al., 2011). Out of 73 subjects (CC 21, TT11; CT 41) the midazolam metabolite ratio was greater in the TT group compared with carriers of the C allele. The p.A503V variant of POR had increased 1-hydroxylation of midazolam. Further analysis showed association with hepatic but not intestinal CYP3A activities (Yang et al., 2011). There was no significant differences in combined hepatic plus intestinal CYP3A activity.

A study tested the impact of POR p.A503V on metabolism of tacrolimus (de Jonge et al., 2011). They found lower levels of tacrolimus in carriers of p.A503V allele but in the individuals with CYP3A5*3/*3 allele, the p.A503V POR had no effect (de Jonge et al., 2011). Another study measured the impact of p.A503V (rs1057868, DNA change GCC to GTC) allele of POR on metabolism of tacrolimus in healthy Chinese men (Zhang et al., 2013). There was no difference in tacrolimus metabolism between two POR alleles. Further analysis showed no significant differences in tacrolimus pharmacokinetics in CYP3A5 non-expressers (CYP3A5*3/*3). The mean tacrolimus exposure for the p.A503V CC homozygotes in CYP3A5 expressers (CYP3A5*1/*1 or *1/*3) were much higher than the p.A503V CT heterozygotes. These studies suggest a role for p.A503V allele of POR in the variability of tacrolimus exposure levels. In vitro studies of CYP3A5 activities comparing normal and p.A503V variants of POR may confirm this hypothesis.

A CYP1A2 genotyping study in smokers also checked POR polymorphic variants for potential linkage to metabolic defects (Dobrinas et al., 2012). During smoking there was no impact of any POR polymorphisms on CYP1A2 activity. CYP1A2 activity increased after smoking cessation in POR rs2302429A and rs1057868T (p.A503V) carriers. The carriers of POR rs2286823A and of rs17148944G-rs10239977C-rs3815455C-rs2286823A-rs2302429G-rs1057868C (503A) had decreased CYP1A2 activity.

Conclusions

PORD is more complex than any single enzyme or protein deficiency (Janner et al., 2006; Flück et al., 2011c; Camats et al., 2012). It affects drug and xenobiotic metabolism pathways (Henderson et al., 2006; Flück et al., 2010; Nicolo et al., 2010). Variants of POR have different interactions with different redox partners. Effect of POR variants on drug metabolizing P450 enzymes needs detailed studies. Deposition of heme in liver lowers cytochrome P450 levels and enzymatic activities (Pandey et al., 1995, 1996). POR variants with lower activities may complicate these symptoms and result in a more severe disease. Heme oxygenase plays a major role in limiting the severity of malaria and sepsis infections (Pamplona et al., 2007; Larsen et al., 2010; Pandey et al., 2010; Ferreira et al., 2011). There may be potential links between the common POR variants and pathogenesis of infections. External flavin supplementation reverts loss of activity of some POR variants (Nicolo et al., 2010). An interesting possibility to explore in future experiments is whether external FMN can receive electrons from bound NADPH in POR as reported for a B. subtilis reductase (Deller et al., 2006). Whether flavin treatment may help patients with POR deficiency remains untested in clinical settings.

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Acknowledgments

This work has been supported by grants to Amit V. Pandey from the Swiss National Science Foundation (31003A-134926), Schweizerischen Mobiliar Genossenschaft Jubiläumsstiftung and Bern University Research Foundation.

References

  1. Agrawal V., Choi J. H., Giacomini K. M., Miller W. L. (2010). Substrate-specific modulation of CYP3A4 activity by genetic variants of cytochrome P450 oxidoreductase. Pharmacogenet. Genomics 20, 611–618 10.1097/FPC.0b013e32833e0cb5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Agrawal V., Huang N., Miller W. L. (2008). Pharmacogenetics of P450 oxidoreductase: effect of sequence variants on activities of CYP1A2 and CYP2C19. Pharmacogenet. Genomics 18, 569–576 10.1097/FPC.0b013e32830054ac [DOI] [PubMed] [Google Scholar]
  3. Biason-Lauber A., Miller W. L., Pandey A. V., Flück C. E. (2013a). Of marsupials and men: “Backdoor” dihydrotestosterone synthesis in male sexual differentiation. Mol. Cell. Endocrinol. 371, 124–132 10.1016/j.mce.2013.01.017 [DOI] [PubMed] [Google Scholar]
  4. Biason-Lauber A., Pandey A. V., Miller W. L., Flück C. E. (2013b). Marsupial pathways in humans, in Genetic Steroid Disorders, eds New M. I., Lekarev O., Parsa A., Yuen T., O'Mally B., Hammer G. (New York, NY: Academic Press; ), 215–224 [Google Scholar]
  5. Bouchoucha N., Samara-Boustani D., Pandey A. V., Bony-Trifunovic H., Hofer G., Aigrain Y., et al. (2014). Characterization of a novel CYP19A1 (aromatase) R192H mutation causing virilization of a 46,XX newborn, undervirilization of the 46, XY brother, but no virilization of the mother during pregnancies. Mol. Cell. Endocrinol. 390, 8–17 10.1016/j.mce.2014.03.008 [DOI] [PubMed] [Google Scholar]
  6. But W. M., Lo I. F., Shek C. C., Tse W. Y., Lam S. T. (2010). Ambiguous genitalia, impaired steroidogenesis, and Antley-Bixler syndrome in a patient with P450 oxidoreductase deficiency. Hong Kong Med. J. 16, 59–62 Available online at: http://www.hkmj.org/article_pdfs/hkm1002p59.pdf [PubMed] [Google Scholar]
  7. Camats N., Pandey A. V., Fernandez-Cancio M., Andaluz P., Janner M., Toran N., et al. (2012). Ten novel mutations in the NR5A1 gene cause disordered sex development in 46, XY and ovarian insufficiency in 46, XX individuals. J. Clin. Endocrinol. Metab. 97, E1294–E1306 10.1210/jc.2011-3169 [DOI] [PubMed] [Google Scholar]
  8. de Jonge H., Metalidis C., Naesens M., Lambrechts D., Kuypers D. R. (2011). The P450 oxidoreductase *28 SNP is associated with low initial tacrolimus exposure and increased dose requirements in CYP3A5-expressing renal recipients. Pharmacogenomics 12, 1281–1291 10.2217/pgs.11.77 [DOI] [PubMed] [Google Scholar]
  9. Deller S., Sollner S., Trenker-El-Toukhy R., Jelesarov I., Gubitz G. M., Macheroux P. (2006). Characterization of a thermostable NADPH:FMN oxidoreductase from the mesophilic bacterium Bacillus subtilis. Biochemistry 45, 7083–7091 10.1021/bi052478r [DOI] [PubMed] [Google Scholar]
  10. Dhir V., Ivison H. E., Krone N., Shackleton C. H., Doherty A. J., Stewart P. M., et al. (2007). Differential inhibition of CYP17A1 and CYP21A2 activities by the P450 oxidoreductase mutant A287P. Mol. Endocrinol. 21, 1958–1968 10.1210/me.2007-0066 [DOI] [PubMed] [Google Scholar]
  11. Dobrinas M., Cornuz J., Pedrido L., Eap C. B. (2012). Influence of cytochrome P450 oxidoreductase genetic polymorphisms on CYP1A2 activity and inducibility by smoking. Pharmacogenet. Genomics 22, 143–151 10.1097/FPC.0b013e32834e9e1a [DOI] [PubMed] [Google Scholar]
  12. Ferreira A., Marguti I., Bechmann I., Jeney V., Chora A., Palha N. R., et al. (2011). Sickle hemoglobin confers tolerance to Plasmodium infection. Cell 145, 398–409 10.1016/j.cell.2011.03.049 [DOI] [PubMed] [Google Scholar]
  13. Flück C. E., Mallet D., Hofer G., Samara-Boustani D., Leger J., Polak M., et al. (2011a). Deletion of P399_E401 in NADPH cytochrome P450 oxidoreductase results in partial mixed oxidase deficiency. Biochem. Biophys. Res. Commun. 412, 572–577 10.1016/j.bbrc.2011.08.001 [DOI] [PubMed] [Google Scholar]
  14. Flück C. E., Meyer-Böni M., Pandey A. V., Kempna P., Miller W. L., Schoenle E. J., et al. (2011b). Why boys will be boys: two pathways of fetal testicular androgen biosynthesis are needed for male sexual differentiation. Am. J. Hum. Genet. 89, 201–218 10.1016/j.ajhg.2011.06.009 [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Flück C. E., Mullis P. E., Pandey A. V. (2010). Reduction in hepatic drug metabolizing CYP3A4 activities caused by P450 oxidoreductase mutations identified in patients with disordered steroid metabolism. Biochem. Biophys. Res. Commun. 401, 149–153 10.1016/j.bbrc.2010.09.035 [DOI] [PubMed] [Google Scholar]
  16. Flück C. E., Nicolo C., Pandey A. V. (2007). Clinical, structural and functional implications of mutations and polymorphisms in human NADPH P450 oxidoreductase. Fundam. Clin. Pharmacol. 21, 399–410 10.1111/j.1472-8206.2007.00520.x [DOI] [PubMed] [Google Scholar]
  17. Flück C. E., Pandey A. V. (2011). Clinical and biochemical consequences of p450 oxidoreductase deficiency. Endocr. Dev. 20, 63–79 10.1159/000321221 [DOI] [PubMed] [Google Scholar]
  18. Flück C. E., Pandey A. V. (2013). P450 oxidoreductase deficiency (PORD), in Genetic Steroid Disorders, eds New M. I., Lekarev O., Parsa A., Yuen T., O'Mally B., Hammer G. (New York, NY: Academic Press; ), 125–143 [Google Scholar]
  19. Flück C. E., Pandey A. V. (in press). Steroidogenesis of the testis – new genes and pathways. Ann. Endocrinol. 10.1016/j.ando.2014.03.002 [DOI] [PubMed] [Google Scholar]
  20. Flück C. E., Pandey A. V., Dick B., Camats N., Fernandez-Cancio M., Clemente M., et al. (2011c). Characterization of novel StAR (Steroidogenic Acute Regulatory Protein) mutations causing non-classic lipoid adrenal hyperplasia. PLoS ONE 6:e20178 10.1371/journal.pone.0020178 [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Flück C. E., Tajima T., Pandey A. V., Arlt W., Okuhara K., Verge C. F., et al. (2004). Mutant P450 oxidoreductase causes disordered steroidogenesis with and without Antley-Bixler syndrome. Nat. Genet. 36, 228–230 10.1038/ng1300 [DOI] [PubMed] [Google Scholar]
  22. Fukami M., Homma K., Hasegawa T., Ogata T. (2013). Backdoor pathway for dihydrotestosterone biosynthesis: implications for normal and abnormal human sex development. Dev. Dyn. 242, 320–329 10.1002/dvdy.23892 [DOI] [PubMed] [Google Scholar]
  23. Gomes A. M., Winter S., Klein K., Turpeinen M., Schaeffeler E., Schwab M., et al. (2009). Pharmacogenomics of human liver cytochrome P450 oxidoreductase: multifactorial analysis and impact on microsomal drug oxidation. Pharmacogenomics 10, 579–599 10.2217/pgs.09.7 [DOI] [PubMed] [Google Scholar]
  24. Gu J., Weng Y., Zhang Q. Y., Cui H., Behr M., Wu L., et al. (2003). Liver-specific deletion of the NADPH-cytochrome P450 reductase gene: impact on plasma cholesterol homeostasis and the function and regulation of microsomal cytochrome P450 and heme oxygenase. J. Biol. Chem. 278, 25895–25901 10.1074/jbc.M303125200 [DOI] [PubMed] [Google Scholar]
  25. Haiman C. A., Setiawan V. W., Xia L. Y., Le Marchand L., Ingles S. A., Ursin G., et al. (2007). A variant in the cytochrome p450 oxidoreductase gene is associated with breast cancer risk in African Americans. Cancer Res. 67, 3565–3568 10.1158/0008-5472.CAN-06-4801 [DOI] [PubMed] [Google Scholar]
  26. Hart S. N., Wang S., Nakamoto K., Wesselman C., Li Y., Zhong X. B. (2008). Genetic polymorphisms in cytochrome P450 oxidoreductase influence microsomal P450-catalyzed drug metabolism. Pharmacogenet. Genomics 18, 11–24 10.1097/FPC.0b013e3282f2f121 [DOI] [PubMed] [Google Scholar]
  27. Henderson C. J., Otto D. M., Carrie D., Magnuson M. A., McLaren A. W., Rosewell I., et al. (2003). Inactivation of the hepatic cytochrome P450 system by conditional deletion of hepatic cytochrome P450 reductase. J. Biol. Chem. 278, 13480–13486 10.1074/jbc.M212087200 [DOI] [PubMed] [Google Scholar]
  28. Henderson C. J., Pass G. J., Wolf C. R. (2006). The hepatic cytochrome P450 reductase null mouse as a tool to identify a successful candidate entity. Toxicol. Lett. 162, 111–117 10.1016/j.toxlet.2005.10.016 [DOI] [PubMed] [Google Scholar]
  29. Herkert J. C., Blaauwwiekel E. E., Hoek A., Veenstra-Knol H. E., Kema I. P., Arlt W., et al. (2011). A rare cause of congenital adrenal hyperplasia: Antley-Bixler syndrome due to POR deficiency. Neth. J. Med. 69, 281–283 Available online at: http://www.njmonline.nl/getpdf.php?t=a&id=10000734 [PubMed] [Google Scholar]
  30. Huang N., Agrawal V., Giacomini K. M., Miller W. L. (2008). Genetics of P450 oxidoreductase: sequence variation in 842 individuals of four ethnicities and activities of 15 missense mutations. Proc. Natl. Acad. Sci. U.S.A. 105, 1733–1738 10.1073/pnas.0711621105 [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Huang N., Pandey A. V., Agrawal V., Reardon W., Lapunzina P. D., Mowat D., et al. (2005). Diversity and function of mutations in p450 oxidoreductase in patients with Antley-Bixler syndrome and disordered steroidogenesis. Am. J. Hum. Genet. 76, 729–749 10.1086/429417 [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Idkowiak J., Malunowicz E. M., Dhir V., Reisch N., Szarras-Czapnik M., Holmes D. M., et al. (2010). Concomitant mutations in the P450 oxidoreductase and androgen receptor genes presenting with 46,XY disordered sex development and androgenization at adrenarche. J. Clin. Endocrinol. Metab. 95, 3418–3427 10.1210/jc.2010-0058 [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Janner M., Pandey A. V., Mullis P. E., Flück C. E. (2006). Clinical and biochemical description of a novel CYP21A2 gene mutation 962_963insA using a new 3D model for the P450c21 protein. Eur. J. Endocrinol. 155, 143–151 10.1530/eje.1.02172 [DOI] [PubMed] [Google Scholar]
  34. Klein K., Zanger U. M. (2013). Pharmacogenomics of cytochrome P450 3A4: recent progress toward the “Missing Heritability” problem. Front. Genet. 4:12 10.3389/fgene.2013.00012 [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Ko J. M., Cheon C. K., Kim G. H., Yoo H. W. (2009). A case of Antley-Bixler syndrome caused by compound heterozygous mutations of the cytochrome P450 oxidoreductase gene. Eur. J. Pediatr. 168, 877–880 10.1007/s00431-008-0849-0 [DOI] [PubMed] [Google Scholar]
  36. Kranendonk M., Marohnic C. C., Panda S. P., Duarte M. P., Oliveira J. S., Masters B. S., et al. (2008). Impairment of human CYP1A2-mediated xenobiotic metabolism by Antley-Bixler syndrome variants of cytochrome P450 oxidoreductase. Arch. Biochem. Biophys. 475, 93–99 10.1016/j.abb.2008.04.014 [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Krone N., Reisch N., Idkowiak J., Dhir V., Ivison H. E., Hughes B. A., et al. (2012). Genotype-phenotype analysis in congenital adrenal hyperplasia due to P450 oxidoreductase deficiency. J. Clin. Endocrinol. Metab. 97, E257–E267 10.1210/jc.2011-0640 [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Larsen R., Gozzelino R., Jeney V., Tokaji L., Bozza F. A., Japiassu A. M., et al. (2010). A central role for free heme in the pathogenesis of severe sepsis. Sci. Transl. Med. 2, 51ra71 10.1126/scitranslmed.3001118 [DOI] [PubMed] [Google Scholar]
  39. Marohnic C. C., Panda S. P., McCammon K., Rueff J., Masters B. S., Kranendonk M. (2010). Human cytochrome P450 oxidoreductase deficiency caused by the Y181D mutation: molecular consequences and rescue of defect. Drug Metab. Dispos. 38, 332–340 10.1124/dmd.109.030445 [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Meyer U. A., Zanger U. M., Schwab M. (2013). Omics and drug response. Annu. Rev. Pharmacol. Toxicol. 53, 475–502 10.1146/annurev-pharmtox-010510-100502 [DOI] [PubMed] [Google Scholar]
  41. Miller W. L., Auchus R. J. (2011). The molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders. Endocr. Rev. 32, 81–151 10.1210/er.2010-0013 [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Miller W. L., Huang N., Agrawal V., Giacomini K. M. (2009). Genetic variation in human P450 oxidoreductase. Mol. Cell. Endocrinol. 300, 180–184 10.1016/j.mce.2008.09.017 [DOI] [PubMed] [Google Scholar]
  43. Miller W. L., Huang N., Flück C. E., Pandey A. V. (2004). P450 oxidoreductase deficiency. Lancet 364, 1663 10.1016/S0140-6736(04)17344-3 [DOI] [PubMed] [Google Scholar]
  44. Moutinho D., Marohnic C. C., Panda S. P., Rueff J., Masters B. S., Kranendonk M. (2012). Altered human CYP3A4 activity caused by Antley-Bixler syndrome-related variants of NADPH-cytochrome P450 oxidoreductase measured in a robust in vitro system. Drug Metab. Dispos. 40, 754–760 10.1124/dmd.111.042820 [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Nicolo C., Flück C. E., Mullis P. E., Pandey A. V. (2010). Restoration of mutant cytochrome P450 reductase activity by external flavin. Mol. Cell. Endocrinol. 321, 245–252 10.1016/j.mce.2010.02.024 [DOI] [PubMed] [Google Scholar]
  46. Oneda B., Crettol S., Jaquenoud Sirot E., Bochud M., Ansermot N., Eap C. B. (2009). The P450 oxidoreductase genotype is associated with CYP3A activity in vivo as measured by the midazolam phenotyping test. Pharmacogenet. Genomics 19, 877–883 10.1097/FPC.0b013e32833225e7 [DOI] [PubMed] [Google Scholar]
  47. Otto D. M., Henderson C. J., Carrie D., Davey M., Gundersen T. E., Blomhoff R., et al. (2003). Identification of novel roles of the cytochrome P450 system in early embryogenesis: effects on vasculogenesis and retinoic acid homeostasis. Mol. Cell. Biol. 23, 6103–6116 10.1128/MCB.23.17.6103-6116.2003 [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Pamplona A., Ferreira A., Balla J., Jeney V., Balla G., Epiphanio S., et al. (2007). Heme oxygenase-1 and carbon monoxide suppress the pathogenesis of experimental cerebral malaria. Nat. Med. 13, 703–710 10.1038/nm1586 [DOI] [PubMed] [Google Scholar]
  49. Pandey A. V., Flück C. E. (2013). NADPH P450 oxidoreductase: structure, function, and pathology of diseases. Pharmacol. Ther. 138, 229–254 10.1016/j.pharmthera.2013.01.010 [DOI] [PubMed] [Google Scholar]
  50. Pandey A. V., Flück C. E., Huang N., Tajima T., Fujieda K., Miller W. L. (2004). P450 oxidoreductase deficiency: a new disorder of steroidogenesis affecting all microsomal P450 enzymes. Endocr. Res. 30, 881–888 10.1081/ERC-200044134 [DOI] [PubMed] [Google Scholar]
  51. Pandey A. V., Flück C. E., Mullis P. E. (2010). Altered heme catabolism by heme oxygenase-1 caused by mutations in human NADPH cytochrome P450 reductase. Biochem. Biophys. Res. Commun. 400, 374–378 10.1016/j.bbrc.2010.08.072 [DOI] [PubMed] [Google Scholar]
  52. Pandey A. V., Kempna P., Hofer G., Mullis P. E., Flück C. E. (2007). Modulation of human CYP19A1 activity by mutant NADPH P450 oxidoreductase. Mol. Endocrinol. 21, 2579–2595 10.1210/me.2007-0245 [DOI] [PubMed] [Google Scholar]
  53. Pandey A. V., Tekwani B. L., Pandey V. C. (1995). Characterization of hemozoin from liver and spleen of mice infected with Plasmodium yoelli, a rodent malaria parasite. Biomed. Res. Tokyo 16, 115–120 [Google Scholar]
  54. Pandey A. V., Tekwani B. L., Pandey V. C. (1996). Effect of Plasmodium yoelii infection on constitutive and phenobarbitone inducible mixed function oxidase system of mice. J. Parasitic Dis. 20, 141–144 [Google Scholar]
  55. Peterson R. E., Imperato-McGinley J., Gautier T., Shackleton C. H. L. (1985). Male pseudohermaphroditism due to multiple defects in steroid-biosynthetic microsomal mixed-function oxidases. A new variant of congenital adrenal hyperplasia. N. Engl. J. Med. 313, 1182–1191 10.1056/NEJM198511073131903 [DOI] [PubMed] [Google Scholar]
  56. Porter T. D., Banerjee S., Stolarczyk E. I., Zou L. (2011). Suppression of cytochrome P450 reductase (POR) expression in hepatoma cells replicates the hepatic lipidosis observed in hepatic POR-null mice. Drug Metab. Dispos. 39, 966–973 10.1124/dmd.111.038562 [DOI] [PMC free article] [PubMed] [Google Scholar]
  57. Puiu M., Pienar C., Emandi A. C., Arghirescu S., Popa C., Micle I. (2012). A case of Antley Bixler syndrome: diagnosis and outcome. Acta Endocrinol. Buch. 8, 479–484 10.4183/aeb.2012.479 [DOI] [Google Scholar]
  58. Riddick D. S., Ding X., Wolf C. R., Porter T. D., Pandey A. V., Zhang Q. Y., et al. (2013). NADPH-cytochrome P450 oxidoreductase: roles in physiology, pharmacology, and toxicology. Drug Metab. Dispos. 41, 12–23 10.1124/dmd.112.048991 [DOI] [PMC free article] [PubMed] [Google Scholar]
  59. Saito Y., Yamamoto N., Katori N., Maekawa K., Fukushima-Uesaka H., Sugimoto D., et al. (2011). Genetic polymorphisms and haplotypes of por, encoding cytochrome p450 oxidoreductase, in a Japanese population. Drug Metab. Pharmacokinet. 26, 107–116 10.2133/dmpk.DMPK-10-SC-096 [DOI] [PubMed] [Google Scholar]
  60. Sandee D., Morrissey K., Agrawal V., Tam H. K., Kramer M. A., Tracy T. S., et al. (2010). Effects of genetic variants of human P450 oxidoreductase on catalysis by CYP2D6 in vitro. Pharmacogenet. Genomics 20, 677–686 10.1097/FPC.0b013e32833f4f9b [DOI] [PMC free article] [PubMed] [Google Scholar]
  61. Shen A. L., O'Leary K. A., Kasper C. B. (2002). Association of multiple developmental defects and embryonic lethality with loss of microsomal NADPH-cytochrome P450 oxidoreductase. J. Biol. Chem. 277, 6536–6541 10.1074/jbc.M111408200 [DOI] [PubMed] [Google Scholar]
  62. Sim S. C., Miller W. L., Zhong X. B., Arlt W., Ogata T., Ding X., et al. (2009). Nomenclature for alleles of the cytochrome P450 oxidoreductase gene. Pharmacogenet. Genomics 19, 565–566 10.1097/FPC.0b013e32832af5b7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  63. Solus J. F., Arietta B. J., Harris J. R., Sexton D. P., Steward J. Q., McMunn C., et al. (2004). Genetic variation in eleven phase I drug metabolism genes in an ethnically diverse population. Pharmacogenomics 5, 895–931 10.1517/14622416.5.7.895 [DOI] [PubMed] [Google Scholar]
  64. Subramanian M., Agrawal V., Sandee D., Tam H. K., Miller W. L., Tracy T. S. (2012). Effect of P450 oxidoreductase variants on the metabolism of model substrates mediated by CYP2C9.1, CYP2C9.2, and CYP2C9.3. Pharmacogenet. Genomics 22, 590–597 10.1097/FPC.0b013e3283544062 [DOI] [PubMed] [Google Scholar]
  65. Tomalik-Scharte D., Maiter D., Kirchheiner J., Ivison H. E., Fuhr U., Arlt W. (2010). Impaired hepatic drug and steroid metabolism in congenital adrenal hyperplasia due to P450 oxidoreductase deficiency. Eur. J. Endocrinol. 163, 919–924 10.1530/EJE-10-0764 [DOI] [PMC free article] [PubMed] [Google Scholar]
  66. Tomkova M., Marohnic C. C., Gurwitz D., Seda O., Masters B. S., Martasek P. (2012). Identification of six novel P450 oxidoreductase missense variants in Ashkenazi and Moroccan Jewish populations. Pharmacogenomics 13, 543–554 10.2217/pgs.12.21 [DOI] [PMC free article] [PubMed] [Google Scholar]
  67. Utriainen P., Laakso S., Jaaskelainen J., Voutilainen R. (2012). Polymorphisms of POR, SULT2A1 and HSD11B1 in children with premature adrenarche. Metabolism 61, 1215–1219 10.1016/j.metabol.2012.02.008 [DOI] [PubMed] [Google Scholar]
  68. Xia C., Panda S. P., Marohnic C. C., Martasek P., Masters B. S., Kim J. J. (2011). Structural basis for human NADPH-cytochrome P450 oxidoreductase deficiency. Proc. Natl. Acad. Sci. U.S.A. 108, 13486–13491 10.1073/pnas.1106632108 [DOI] [PMC free article] [PubMed] [Google Scholar]
  69. Yang G., Fu Z., Chen X., Yuan H., Yang H., Huang Y., et al. (2011). Effects of the CYP oxidoreductase Ala503Val polymorphism on CYP3A activity in vivo: a randomized, open-label, crossover study in healthy Chinese men. Clin. Ther. 33, 2060–2070 10.1016/j.clinthera.2011.11.004 [DOI] [PubMed] [Google Scholar]
  70. Zanger U. M., Schwab M. (2013). Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol. Ther. 138, 103–141 10.1016/j.pharmthera.2012.12.007 [DOI] [PubMed] [Google Scholar]
  71. Zhang J. J., Zhang H., Ding X. L., Ma S., Miao L. Y. (2013). Effect of the P450 oxidoreductase *28 polymorphism on the pharmacokinetics of tacrolimus in Chinese healthy male volunteers. Eur. J. Clin. Pharmacol. 69, 807–812 10.1007/s00228-012-1432-1 [DOI] [PubMed] [Google Scholar]
  72. Zhang X., Li L., Ding X., Kaminsky L. S. (2011). Identification of cytochrome P450 oxidoreductase gene variants that are significantly associated with the interindividual variations in warfarin maintenance dose. Drug Metab. Dispos. 39, 1433–1439 10.1124/dmd.111.038836 [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Frontiers in Pharmacology are provided here courtesy of Frontiers Media SA

RESOURCES